| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Dec 13, 2016 | EGRX Eagle Pharmaceuticals, Inc. | Krill Steven L. | EVP &Chief Scientific Officer | Sell | 10,000 | $73.62 | $736,163.00 | -100% | |
| Dec 12, 2016 | BHC Bausch Health Companies Inc. | Pershing Square Capital Management, L.P.74 | Director | Sell | 3,476,690 | $14.85 | $51,628,846.50 | -16.1% | |
| Dec 12, 2016 | ALKS Alkermes Plc. | Ehrich Elliot | EVP, R&D &CMO, Alkermes, Inc. | Sell | 16,983 | $55.15 | $936,631.13 | -24.4% | |
| Dec 8, 2016 | SNOA Sonoma Pharmaceuticals, Inc. | Miller Robert E | Chief Financial Officer | Buy | 5,000 | $4.86 | $24,300.00 | +291.7% | |
| Dec 8, 2016 | SNOA Sonoma Pharmaceuticals, Inc. | Schutz James J | Chief Executive Officer | Buy | 1,000 | $4.88 | $4,880.00 | +10.0% | |
| Dec 8, 2016 | ALKS Alkermes Plc. | Biberstein Kathryn L | Evp/ Cao/ CCO Alks Inc; Sec Alks | Sell | 14,145 | $56.13 | $793,966.61 | -8.3% | |
| Dec 7, 2016 | ALKS Alkermes Plc. | Frates James M83 | SVP, Alks Inc; CFO Alks | Sell | 23,731 | $56.28 | $1,335,631.93 | -6.2% | |
| Dec 5, 2016 | IRWD Ironwood Pharmaceuticals Inc | Olanoff Lawrence S | Director | Sell | 3,200 | $15.68 | $50,176.00 | -10.9% | |
| Dec 5, 2016 | AMPH Amphastar Pharmaceuticals, Inc. | Zhou Rong59 | EVP, Production Center | Sell | 61 | $20.70 | $1,262.43 | -0.2% | |
| Dec 1, 2016 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 400 | $20.26 | $8,104.00 | -0.7% | |
| Dec 1, 2016 | ALKS Alkermes Plc. | Biberstein Kathryn L | Evp/ Cao/ CCO Alks Inc; Sec Alks | Sell | 15,000 | $56.13 | $841,988.91 | -15.1% | |
| Nov 30, 2016 | ALKS Alkermes Plc. | Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | Sell | 10,000 | $57.51 | $575,083.00 | -3.1% | |
| Nov 30, 2016 | EGRX Eagle Pharmaceuticals, Inc. | Krill Steven L. | EVP &Chief Scientific Officer | Sell | 5,987 | $80.00 | $478,960.00 | -100% | |
| Nov 29, 2016 | ALKS Alkermes Plc. | Pops Richard F57 | Director And CEO, Alkermes Plc | Sell | 30,000 | $56.98 | $1,709,469.25 | -2.4% | |
| Nov 29, 2016 | AVDL Avadel Pharmaceuticals Plc | Stapleton Craig R | Director | Buy | 20,000 | $10.79 | $215,870.00 | +40.0% | |
| Nov 28, 2016 | EGRX Eagle Pharmaceuticals, Inc. | Flaum Sander A | Director | Sell | 5,000 | $78.66 | $393,300.00 | -30.5% | |
| Nov 28, 2016 | AMPH Amphastar Pharmaceuticals, Inc. | Shandell Jason B. | President And General Counsel | Sell | 26,335 | $20.48 | $539,258.16 | -6.1% | |
| Nov 25, 2016 | PRGO Perrigo Co Plc | Brown Judy L | EVP, Business Ops &CFO | Sell | 2,097 | $89.44 | $187,555.68 | -17.3% | |
| Nov 22, 2016 | ALKS Alkermes Plc. | Pops Richard F57 | Director And CEO, Alkermes Plc | Sell | 30,000 | $58.66 | $1,759,935.64 | -2.4% | |
| Nov 21, 2016 | PRGO Perrigo Co Plc | Parker Geoffrey M.46 | Director | Buy | 2,500 | $88.75 | $221,875.00 | New | |
| Nov 21, 2016 | LNTH Lantheus Holdings, Inc. | Avista Capital Partners Gp, LLC | 10% Owner | Sell | 2,500,000 | $9.00 | $22,500,000.00 | -14.0% | |
| Nov 21, 2016 | LNTH Lantheus Holdings, Inc. | Venkataraman Sriram | Director, 10% Owner | Sell | 2,500,000 | $9.00 | $22,500,000.00 | -14.0% | |
| Nov 21, 2016 | PRGO Perrigo Co Plc | Kingma Todd W | Executive VP, General Counsel | Sell | 750 | $88.68 | $66,511.50 | -4.9% | |
| Nov 21, 2016 | AVDL Avadel Pharmaceuticals Plc | Anderson Michael S | Chief Executive Officer | Buy | 2,000 | $10.64 | $21,274.00 | +1.0% | |
| Nov 21, 2016 | LNTH Lantheus Holdings, Inc. | Burgstahler David F | Director, 10% Owner | Sell | 2,500,000 | $9.00 | $22,500,000.00 | -14.0% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.